India, Oct. 7 -- Alvotech (ALVO), a biotechnology company focused on biosimilar medicines, said it has entered into a long-term strategic manufacturing agreement with LOTTE Biologics to increase global supply capacity.
Under the agreement, LOTTE Biologics will manufacture drug substance for multiple antibody biosimilar products at its Syracuse, New York facility for global supply, with the potential to expand the collaboration over time.
The Syracuse facility has 40,000 liters of bioreactor capacity for biologics manufacturing, along with on-site process development and quality control capabilities. The facility recently completed an unannounced FDA inspection with zero observations.
The agreement expands Alvotech's U.S.-based manufactur...